webleads-tracker

Pharma Compliance Info Corporate reputation of pharma in Europe | The patient perspective - 34 companies reviewed Marketing & Market Access

Corporate reputation of pharma in Europe | The patient perspective – 34 companies reviewed

European patient groups fear pharma’s pricing tactics are causing health inequities.
Pharma Compliance Info Corporate reputation of pharma in Europe | The patient perspective - 34 companies reviewed Marketing & Market Access   Percentage of patient groups world believing pharma to be “Poor” at setting fair pricing policies (2014)
(Numbers in brackets are the number of respondent patient groups)

KEY FINDINGS
Europe-based patient groups regard pharma more positively in 2014 than they did in 2013: 26% of the patient groups responding to the 2014 Corporate-Reputation survey say that the industry’s corporate reputation has improved (against 18.9% saying the same in 2013).
But, even so, European patient groups express mixed emotions in 2014 about aspects of pharma: from the hope engendered in patients by a number of important new clinical trials, to the disbelief that reimbursement authorities refuse to approve some of pharma’s latest products on the grounds of the high prices set by the companies.
The lowest ratings awarded by Europe-based patient groups to pharma activities in 2014 relate to the ability (or otherwise) of pharma companies to implement fair pricing policies. As many as 43.4% of the 550 respondent Europe-based patient groups think pharma poor at pricing products fairly. This opinion is held by 63% of French patient groups, by 57% of those in Italy, 53% in Germany, 53% in the UK, and 50% in Austria [see chart, below].
Comments offered by the respondent Europe-based patient groups show that areas of distrust between patient groups and pharma include the following: pharma corruption scandals, and litigation against pharma; the possibility that health professionals may be in the pocket of the industry; absence of robust science when presenting clinical data; lack of patient access to expensive new drugs; excessive profit-making; and … not taking patients’ needs and viewpoints into consideration.

For further information about PatientView’s ‘Corporate Reputation of Pharma’ series of reports, access to a PDF version of this press statement, and report pricing, go to http://www.patient-view.com/bull-corp-reputation.html

Check Also

Pharma Compliance Info Rapport du Sénat sur les Médicaments innovants | CONSOLIDER LE MODÈLE FRANÇAIS D’ACCÈS PRÉCOCE Marketing & Market Access

Rapport du Sénat sur les Médicaments innovants | CONSOLIDER LE MODÈLE FRANÇAIS D’ACCÈS PRÉCOCE

Rapport d’information de M. Yves DAUDIGNY, Mmes Catherine DEROCHE et Véronique GUILLOTIN, fait au nom …

X